ClaPD regimen: Difference between revisions
No edit summary |
|||
Line 16: | Line 16: | ||
==Indications== | ==Indications== | ||
*Relapsed or refractory [[Multiple Myeloma]] | *Relapsed or refractory [[Multiple Myeloma]]<ref>{{citeweb| url = https://ash.confex.com/ash/2011/webprogram/Paper40918.html | title = ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma }}</ref> | ||
==References== | ==References== |
Revision as of 12:47, 12 March 2015
WikiDoc Resources for ClaPD regimen |
Articles |
---|
Most recent articles on ClaPD regimen Most cited articles on ClaPD regimen |
Media |
Powerpoint slides on ClaPD regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ClaPD regimen at Clinical Trials.gov Trial results on ClaPD regimen Clinical Trials on ClaPD regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ClaPD regimen NICE Guidance on ClaPD regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on ClaPD regimen Discussion groups on ClaPD regimen Patient Handouts on ClaPD regimen Directions to Hospitals Treating ClaPD regimen Risk calculators and risk factors for ClaPD regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for ClaPD regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:
Overview
ClaPD regimen refers to a regimen consisting of Clarithromycin, Pomalidomide, Dexamethasone therapy in relapsed or refractory Multiple Myeloma
Regimen
ClaClarithromycin
PPomalidomide
DDexamethasone
Indications
- Relapsed or refractory Multiple Myeloma[1]